Hostname: page-component-7479d7b7d-k7p5g Total loading time: 0 Render date: 2024-07-09T09:26:56.288Z Has data issue: false hasContentIssue false

Osteoclastic activity in chronic otitis media with cholesteatoma-related bone destruction

Published online by Cambridge University Press:  05 August 2021

A Özgür*
Affiliation:
İstanbul Yeni Yüzyıl University Gaziosmanpaşa Hospital, Department of Otorhinolaryngology, İstanbul, Turkey
T Yemiş
Affiliation:
Department of Otorhinolaryngology, Gümüşhane State Hospital, Gümüşhane/Turkey
E Başbulut
Affiliation:
Microbiology Laboratory, Samsun Education and Research Hospital, Samsun/Turkey
N F Turgut
Affiliation:
Department of Otorhinolaryngology, Samsun Health Practices and Research Centre, University of Health Sciences, Samsun, Turkey
D Özdemir
Affiliation:
Department of Otorhinolaryngology, Samsun Health Practices and Research Centre, University of Health Sciences, Samsun, Turkey
G Akgül
Affiliation:
Department of Otorhinolaryngology, Samsun Health Practices and Research Centre, University of Health Sciences, Samsun, Turkey
D M Mehel
Affiliation:
Department of Otorhinolaryngology, Samsun Health Practices and Research Centre, University of Health Sciences, Samsun, Turkey
M Çelebi
Affiliation:
Department of Otorhinolaryngology, Samsun Health Practices and Research Centre, University of Health Sciences, Samsun, Turkey
*
Author for correspondence: Dr Abdulkadir Özgür, İstanbul Yeni Yüzyıl University Gaziosmanpaşa Hospital Merkez Mah. Cukurcesme Caddesi No: 51 PB: 34245, Gaziosmanpaşa, İstanbul, Turkey E-mail: [email protected]

Abstract

Background

Cholesteatoma-related bone destruction is the cause of many complications due to chronic otitis media. This study aimed to evaluate osteoclastic activity in cholesteatoma-related bone destruction using tartrate-resistant acid phosphatase 5b, an enzyme specific to osteoclastic activity.

Method

Seventy-two patients diagnosed with chronic otitis media were included in this study and were divided into two groups: with and without bone destruction. The blood serum and tissue tartrate-resistant acid phosphatase 5b levels from both groups were compared.

Results

There were no significant differences in the level of serum enzymes between both groups. However, in tissue samples, tartrate-resistant acid phosphatase 5b levels were significantly lower in the bone destruction group than the group without bone destruction.

Conclusion

This study determined that the level of tartrate-resistant acid phosphatase 5b, a specific enzyme for osteoclastic activity in cholesteatoma-related bone destruction, is locally decreased. This data suggests that osteoclastic activity may decrease in cholesteatoma-related bone destruction. However, further experimental and clinical studies are required to clarify this highly complex mechanism.

Type
Main Articles
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr A Özgür takes responsibility for the integrity of the content of the paper

References

Kuo, CL, Liao, WH, Shiao, AS. A review of current progress in acquired cholesteatoma management. Eur Arch Otorhinolaryngol 2015;272:3601–910.1007/s00405-014-3291-0CrossRefGoogle ScholarPubMed
Olszewska, E, Wagner, M, Bernal-Sprekelsen, M, Ebmeyer, J, Dazert, S, Hildmann, H et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 2004;261:624CrossRefGoogle ScholarPubMed
Hamed, MA, Nakata, S, Sayed, RH, Ueda, H, Badawy, BS, Nishimura, Y et al. Pathogenesis and bone resorption in acquired cholesteatoma: current knowledge and future prospectives. Clin Exp Otorhinolaryngol 2016;9:298308CrossRefGoogle ScholarPubMed
Xie, S, Wang, X, Ren, J, Liu, W. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. Eur Arch Otorhinolaryngol 2017;274:2071–8CrossRefGoogle ScholarPubMed
Jeong, JH, Park, CW, Tae, K, Lee, SH, Shin, DH, Kim, KR et al. Expression of RANKL and OPG in middle ear cholesteatoma tissue. Laryngoscope 2006;116:1180–410.1097/01.mlg.0000224345.59291.daCrossRefGoogle ScholarPubMed
Imai, R, Sato, T, Iwamoto, Y, Hanada, Y, Terao, M, Ohta, Y et al. Osteoclasts modulate bone erosion in cholesteatoma via RANKL signaling. J Assoc Res Otolaryngol 2019;20:449–59CrossRefGoogle ScholarPubMed
Koizumi, H, Suzuki, H, Ikezaki, S, Ohbuchi, T, Hashida, K, Sakai, A. Osteoclasts are not activated in middle ear cholesteatoma. J Bone Miner Metab 2016;34:193200CrossRefGoogle Scholar
Koizumi, H, Suzuki, H, Kawaguchi, R, Hashida, K, Hohchi, N, Ohkubo, JI et al. Presence of osteoclasts in middle ear cholesteatoma: a study of undecalcified bone sections. Acta Otolaryngol 2017;137:127–30CrossRefGoogle ScholarPubMed
Yemis, T, Ozgur, A, Basbulut, E, Ozdemir, D, Akgul, G, Mehel, DM et al. Bone turnover in chronic otitis media with bone destruction. Eur Arch Otorhinolaryngol 2020;277:2229–33CrossRefGoogle ScholarPubMed
Oddie, GW, Schenk, G, Angel, NZ, Walsh, N, Guddat, LW, de Jersey, J et al. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone 2000;27:575–8410.1016/S8756-3282(00)00368-9CrossRefGoogle ScholarPubMed
Rissanen, JP, Suominen, MI, Peng, Z, Halleen, JM. Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 2008;82:108–1510.1007/s00223-007-9091-4CrossRefGoogle ScholarPubMed
Lyubimova, NV, Pashkov, MV, Tyulyandin, SA, Gol'dberg, VE, Kushlinskii, NE. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 2004;138:77–9CrossRefGoogle ScholarPubMed
Reithmeier, A, Norgard, M, Ek-Rylander, B, Nareoja, T, Andersson, G. Cathepsin K regulates localization and secretion of tartrate-resistant acid phosphatase (TRAP) in TRAP-overexpressing MDA-MB-231 breast cancer cells. BMC Mol Cell Biol 2020;21:15CrossRefGoogle Scholar
Lv, Y, Wang, G, Xu, W, Tao, P, Lv, X, Wang, Y. Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear kappaB ligand. Exp Ther Med 2015;9:143–6CrossRefGoogle ScholarPubMed
Mira-Pascual, L, Patlaka, C, Desai, S, Paulie, S, Nareoja, T, Lang, P et al. A novel sandwich ELISA for tartrate-resistant acid phosphatase 5a and 5b protein reveals that both isoforms are secreted by differentiating osteoclasts and correlate to the type i collagen degradation marker CTX-I in vivo and in vitro. Calcif Tissue Int 2020;106:194207CrossRefGoogle ScholarPubMed
Hamzei, M, Ventriglia, G, Hagnia, M, Antonopolous, A, Bernal-Sprekelsen, M, Dazert, S et al. Osteoclast stimulating and differentiating factors in human cholesteatoma. Laryngoscope 2003;113:436–42CrossRefGoogle ScholarPubMed
Capeller, B, Caffier, H, Sutterlin, MW, Dietl, J. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 2003;23:1011–15Google ScholarPubMed
Tauchert, S, di Liberto, A, Cordes, T, Thill, M, Salehin, D, Friedrich, M. Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases. Clin Exp Obstet Gynecol 2009;36:219–25Google ScholarPubMed
Chole, RA. Osteoclasts in chronic otitis media, cholesteatoma, and otosclerosis. Ann Otol Rhinol Laryngol 1988;97:661–6CrossRefGoogle ScholarPubMed
Xie, S, Pan, Z, Yin, T, Ren, J, Liu, W. Expression of PTHrP and RANKL in acquired middle ear cholesteatoma epithelium. Acta Otolaryngol 2020;140:351–510.1080/00016489.2020.1717609CrossRefGoogle ScholarPubMed
Walsh, MC, Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol 2014;5:511CrossRefGoogle ScholarPubMed